Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

William C. Hahn, MD, PhD


Medical Oncology


Researcher

  • Executive Vice President and Chief Operating Officer
  • William Rosenberg Professor of Medicine, Harvard Medical School
  • Institute Member, Broad Institute of Harvard and MIT

Centers/Programs

Clinical Interests

  • Prostate cancer
  • Translational research

Contact Information

  • Office Phone Number617-632-3155
  • Fax617-632-2165

Bio

Dr. Hahn received his MD and PhD from Harvard Medical School in 1994. He then completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at DFCI. He conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute and joined the faculty of DFCI and Harvard Medical School in 2001.

Board Certification:

  • Internal Medicine, 1997
  • Medical Oncology, 2000

Fellowship:

  • Dana-Farber/Partners CancerCare, Medical Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • Elected to the American Society of Clinical Investigation 2005
  • Wilson S. Stone Memorial Award, MD Anderson Cancer Center 2000
  • Gill-Simonian Prize for Mentoring 2008
  • Ho-Am Laureate in Medicine 2010
  • Elected to Association of American Physicians 2013

Research

Functional genomics and human cell transformation, Precision cancer medicine

My work as a physician-scientist involves both the care of cancer patients and biomedical research directed toward a greater understanding of the mechanisms involved in malignant transformation. My laboratory focuses on understanding the cooperative interactions that conspire to transform human cells. To address this question, we have developed new experimental models of human cancer of defined genetic composition, created methods to perform systematic interrogation of gene function in mammalian cells and tissues and help optimize new approaches to integrate genome scale data. Using these approaches, we have identified and credential new oncogenes and tumor suppressor genes and have performed preclinical studies that will form the foundation necessary for translational studies in patients.

Specifically, we have developed genetic methods that permit the construction of genetically defined, experimental models of the major human epithelial cancers from primary human cells through the manipulation of oncogenes, tumor suppressor genes and telomerase. These model systems have permitted us to study the molecular interactions that lead to cancer. In addition, we have performed proof-of-principle experiments that such experimental models will prove useful in the discovery and validation of molecularly targeted therapies. Indeed, these experimental models have allowed us to investigate the mechanisms by which EGFR and other oncogenes and tumor suppressors contribute to cancer initiation. In particular, we have elucidated the role of the PP2A family of serine-threonine phosphatases as tumor suppressor genes.

As a Senior Associate Member of the Broad Institute, I lead efforts to apply functional genomic approaches to cancer. Specifically, I serve as one of the co-principal investigators for the RNAi Consortium (TRC), which has created a genome scale RNA interference library, and have established RNAi screening facilities at both the Broad Institute and the Dana-Farber Cancer Institute (DFCI). In my own laboratory, we are engaged in using these RNAi libraries to apply a comprehensive program to identify cancer vulnerabilities. Using these approaches, we have already discovered several new oncogenes including IKBKE, CDK8, CRKL, CDK6, and PAK1. I also co-direct the Center for Cancer Genome Discovery, which is committed to the development and implementation of technologies that permit the interrogation of cancer-associated mutations at genome scale and to implement these technologies prospectively in newly diagnosed patients.

Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 Jul 14; 13(1):114.
View in: PubMed

Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367.
View in: PubMed

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Apr 29.
View in: PubMed

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
View in: PubMed

A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Mol Cell Biol. 2021 03 24; 41(4).
View in: PubMed

A first-generation pediatric cancer dependency map. Nat Genet. 2021 04; 53(4):529-538.
View in: PubMed

An expanded universe of cancer targets. Cell. 2021 Mar 04; 184(5):1142-1155.
View in: PubMed

Predicting cell health phenotypes using image-based morphology profiling. Mol Biol Cell. 2021 04 19; 32(9):995-1005.
View in: PubMed

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 01 05; 34(1):108532.
View in: PubMed

Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun. 2021 01 04; 12(1):22.
View in: PubMed

Cancer research needs a better map. Nature. 2021 01; 589(7843):514-516.
View in: PubMed

Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493.
View in: PubMed

Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clin Cancer Res. 2020 09 15; 26(18):4995-5006.
View in: PubMed

Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 06; 16(6):635-643.
View in: PubMed

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
View in: PubMed

ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100.
View in: PubMed

STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. Elife. 2020 Jan 08; 9.
View in: PubMed

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat Commun. 2019 12 20; 10(1):5817.
View in: PubMed

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6.
View in: PubMed

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019 10 01; 29(1):118-134.e8.
View in: PubMed

Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Rep. 2019 08 27; 28(9):2331-2344.e8.
View in: PubMed

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604.
View in: PubMed

A CRISPR Way to Identify Cancer Targets. N Engl J Med. 2019 Jun 20; 380(25):2475-2477.
View in: PubMed

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.
View in: PubMed

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079.
View in: PubMed

Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508.
View in: PubMed

The landscape of cancer cell line metabolism. Nat Med. 2019 05; 25(5):850-860.
View in: PubMed

Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019 05 15; 79(10):2564-2579.
View in: PubMed

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
View in: PubMed

Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metab. 2019 05 07; 29(5):1166-1181.e6.
View in: PubMed

MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 06; 17(6):1294-1304.
View in: PubMed

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res. 2019 05 01; 79(9):2404-2414.
View in: PubMed

Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med. 2019 02; 25(2):292-300.
View in: PubMed

Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450.
View in: PubMed

Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018 12 13; 175(7):1972-1988.e16.
View in: PubMed

Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21).
View in: PubMed

Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018 11 02; 9(1):4610.
View in: PubMed

Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387.
View in: PubMed

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018 09; 50(9):1240-1246.
View in: PubMed

iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 11; 17(11):2377-2388.
View in: PubMed

Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Mol Cell. 2018 08 16; 71(4):554-566.e7.
View in: PubMed

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med. 2018 08 01; 8(8).
View in: PubMed

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019 02; 37(1):159-165.
View in: PubMed

An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018 07 30; 7.
View in: PubMed

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
View in: PubMed

Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943.
View in: PubMed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in: PubMed

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13.
View in: PubMed

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.
View in: PubMed

Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. Cell Syst. 2018 05 23; 6(5):555-568.e7.
View in: PubMed

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
View in: PubMed

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1.
View in: PubMed

NetSig: network-based discovery from cancer genomes. Nat Methods. 2018 01; 15(1):61-66.
View in: PubMed

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018 01 02; 128(1):446-462.
View in: PubMed

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448.
View in: PubMed

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 10 31; 6.
View in: PubMed

Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017 Dec; 49(12):1779-1784.
View in: PubMed

A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst. 2017 11 22; 5(5):485-497.e3.
View in: PubMed

Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125.
View in: PubMed

Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst. 2017 08 23; 5(2):105-118.e9.
View in: PubMed

Defining a Cancer Dependency Map. Cell. 2017 Jul 27; 170(3):564-576.e16.
View in: PubMed

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457.
View in: PubMed

PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res. 2017 09 01; 77(17):4613-4625.
View in: PubMed

Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 06 13; 8:15918.
View in: PubMed

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 06 01; 19(6):774-785.
View in: PubMed

Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017 05 31; 6.
View in: PubMed

Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun. 2017 05 23; 8:15403.
View in: PubMed

Going beyond genetics to discover cancer targets. Genome Biol. 2017 05 22; 18(1):95.
View in: PubMed

PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 04 27; 8:15110.
View in: PubMed

PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A. 2017 04 25; 114(17):E3434-E3443.
View in: PubMed

Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017 02 08; 6.
View in: PubMed

ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep. 2017 02 07; 18(6):1543-1557.
View in: PubMed

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 02 01; 6.
View in: PubMed

Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Res. 2017 02 01; 77(3):753-765.
View in: PubMed

Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
View in: PubMed

Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol. 2016; 81:237-246.
View in: PubMed

The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood. 2017 01 26; 129(4):497-508.
View in: PubMed

Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in ß-Catenin-Active Cancers. Cell Syst. 2016 09 28; 3(3):302-316.e4.
View in: PubMed

Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
View in: PubMed

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
View in: PubMed

Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987.
View in: PubMed

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
View in: PubMed

Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016 07; 6(7):714-26.
View in: PubMed

Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016 05; 34(5):539-46.
View in: PubMed

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11; 351(6278):1214-8.
View in: PubMed

TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015 Dec 14; 4:e176.
View in: PubMed

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016 Feb; 14(2):207-15.
View in: PubMed

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015 Dec; 21(12):1491-6.
View in: PubMed

Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. Elife. 2015 Oct 24; 4.
View in: PubMed

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
View in: PubMed

AACR Cancer Progress Report 2015. Clin Cancer Res. 2015 Oct 01; 21(19 Suppl):S1-128.
View in: PubMed

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in: PubMed

Oncogenic Signaling Adaptor Proteins. J Genet Genomics. 2015 Oct 20; 42(10):521-529.
View in: PubMed

Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in: PubMed

Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2015 Jul; 89(13):6971.
View in: PubMed

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43.
View in: PubMed

A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015 Mar 09; 27(3):397-408.
View in: PubMed

Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. J Virol. 2015 Mar; 89(5):2857-65.
View in: PubMed

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7.
View in: PubMed

BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19.
View in: PubMed

Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044.
View in: PubMed

The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res. 2015 Mar; 13(3):502-9.
View in: PubMed

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014 Dec; 124(12):5411-23.
View in: PubMed

RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014 Dec; 46(12):1264-6.
View in: PubMed

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035.
View in: PubMed

The role of specific PP2A complexes in the dephosphorylation of ?H2AX. J Cell Sci. 2015 Jan 15; 128(2):421.
View in: PubMed

Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014 Nov; 16(6):660-72.
View in: PubMed

Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2014 Oct; 88(20):12055-64.
View in: PubMed

Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014 Sep; 16(9):876-88.
View in: PubMed

KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 03; 158(1):171-84.
View in: PubMed

Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One. 2014; 9(6):e99451.
View in: PubMed

PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015 Apr 16; 34(16):2061-71.
View in: PubMed

PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell. 2014 Jun 19; 54(6):932-45.
View in: PubMed

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
View in: PubMed

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23.
View in: PubMed

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23.
View in: PubMed

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
View in: PubMed

ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014 Mar; 20(3):251-4.
View in: PubMed

Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98.
View in: PubMed

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
View in: PubMed

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65.
View in: PubMed

ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014 Jan 30; 6(2):313-24.
View in: PubMed

Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014 Mar; 34(6):1136-44.
View in: PubMed

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5.
View in: PubMed

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7.
View in: PubMed

TRAF2 is an NF-?B-activating oncogene in epithelial cancers. Oncogene. 2015 Jan 08; 34(2):209-16.
View in: PubMed

Genomic insights into WNT/ß-catenin signaling. Trends Pharmacol Sci. 2014 Feb; 35(2):103-9.
View in: PubMed

An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014 Dec 04; 33(49):5637-48.
View in: PubMed

Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013 Nov 26; 110(48):19489-94.
View in: PubMed

The perfect storm: challenges and opportunities for translational medicine. J Clin Invest. 2013 Nov; 123(11):4963-6.
View in: PubMed

A Case of Persistent Helicobacter pylori Infection Occurring with Anti-IgE Immunosuppression. ACG Case Rep J. 2013 Oct; 1(1):16-8.
View in: PubMed

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950.
View in: PubMed

Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5960-71.
View in: PubMed

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
View in: PubMed

Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013 Sep; 3(9):1044-57.
View in: PubMed

HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 06; 153(6):1327-39.
View in: PubMed

The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013 Jun 13; 498(7453):246-50.
View in: PubMed

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013 Jun; 123(6):2551-63.
View in: PubMed

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
View in: PubMed

Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013 Mar 28; 3(3):747-58.
View in: PubMed

IKKe-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013 Mar 28; 3(3):724-33.
View in: PubMed

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
View in: PubMed

Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15; 27(2):197-210.
View in: PubMed

ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2013 Apr; 23(4):665-78.
View in: PubMed

ß-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012 Dec 21; 151(7):1457-73.
View in: PubMed

Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol. 2012 Nov; 14(11):1325-31.
View in: PubMed

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci. 2012 Oct 09; 53(11):6991-6.
View in: PubMed

I?B kinase e phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012 Dec; 32(23):4756-68.
View in: PubMed

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
View in: PubMed

Cancer vulnerabilities unveiled by genomic loss. Cell. 2012 Aug 17; 150(4):842-54.
View in: PubMed

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012 Aug 15; 4(147):147ra112.
View in: PubMed

Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts. Mol Cell Biol. 2012 Oct; 32(19):3963-77.
View in: PubMed

Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012; 8(7):e1002772.
View in: PubMed

Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
View in: PubMed

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012 Aug 02; 120(5):1095-106.
View in: PubMed

Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest. 2012 Jul; 122(7):2369-83.
View in: PubMed

MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal. 2012 May 15; 5(224):rs4.
View in: PubMed

EGFR in limbo. Cell. 2012 May 11; 149(4):735-7.
View in: PubMed

Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84.
View in: PubMed

The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47.
View in: PubMed

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012 Jul 19; 31(29):3397-408.
View in: PubMed

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
View in: PubMed

RMRP is a non-coding RNA essential for early murine development. PLoS One. 2011; 6(10):e26270.
View in: PubMed

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25.
View in: PubMed

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011; 6(9):e24433.
View in: PubMed

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
View in: PubMed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
View in: PubMed

Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311.
View in: PubMed

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7.
View in: PubMed

Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20388-93.
View in: PubMed

The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35.
View in: PubMed

A public genome-scale lentiviral expression library of human ORFs. Nat Methods. 2011 Jun 26; 8(8):659-61.
View in: PubMed

Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. . 2011 Sep; 10(9):1611-23.
View in: PubMed

Towards systematic functional characterization of cancer genomes. Nat Rev Genet. 2011 Jun 17; 12(7):487-98.
View in: PubMed

Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
View in: PubMed

Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502.
View in: PubMed

Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
View in: PubMed

Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55.
View in: PubMed

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
View in: PubMed

Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011 Mar; 13(3):292-302.
View in: PubMed

Therapeutic implications of GIPC1 silencing in cancer. PLoS One. 2010 Dec 30; 5(12):e15581.
View in: PubMed

Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010 Dec 15; 70(24):10474-84.
View in: PubMed

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
View in: PubMed

Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia. 2011 Jan; 82(1):17-33.
View in: PubMed

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
View in: PubMed

Emerging roles for the non-canonical IKKs in cancer. Oncogene. 2011 Feb 10; 30(6):631-41.
View in: PubMed

CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010 Dec; 24(12):2267-80.
View in: PubMed

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010 Nov; 120(11):3940-52.
View in: PubMed

Towards patient-based cancer therapeutics. Nat Biotechnol. 2010 Sep; 28(9):904-6.
View in: PubMed

Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010 Dec; 17(12):1442-52.
View in: PubMed

PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One. 2010 Jul 23; 5(7):e11729.
View in: PubMed

CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer. 2010 Jun 15; 126(12):2863-73.
View in: PubMed

On or off target: mutations, models, and predictions. Sci Transl Med. 2010 Jun 09; 2(35):35ps28.
View in: PubMed

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010 Jun 22; 107(25):11501-6.
View in: PubMed

Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23.
View in: PubMed

Functional genomics and cancer drug target discovery. Curr Opin Mol Ther. 2010 Jun; 12(3):284-93.
View in: PubMed

PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010 May 18; 17(5):497-509.
View in: PubMed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
View in: PubMed

An oncogenic role for ETV1 in melanoma. Cancer Res. 2010 Mar 01; 70(5):2075-84.
View in: PubMed

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010 Mar; 16(3):286-94.
View in: PubMed

CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One. 2010 Feb 01; 5(2):e8979.
View in: PubMed

Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell. 2010 Mar 15; 21(6):1140-52.
View in: PubMed

Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
View in: PubMed

Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 06; 16(5):413-24.
View in: PubMed

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12.
View in: PubMed

Regulating TERT: location, location, location. . 2009 Oct 15; 8(20):3257.
View in: PubMed

Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res. 2009 Oct 15; 69(20):7899-901.
View in: PubMed

Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
View in: PubMed

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42.
View in: PubMed

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 01; 69(19):7803-10.
View in: PubMed

An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009 Sep 10; 461(7261):230-5.
View in: PubMed

SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal. 2009 Jul 21; 2(80):ra35.
View in: PubMed

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
View in: PubMed

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29; 137(5):821-34.
View in: PubMed

Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 2009 May 14; 34(4):461-72.
View in: PubMed

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
View in: PubMed

PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 2009 Apr 01; 69(7):2870-7.
View in: PubMed

Bladder cancer: modeling and translation. Genes Dev. 2009 Mar 15; 23(6):655-9.
View in: PubMed

Integrative genomic approaches to understanding cancer. Biochim Biophys Acta. 2009 Jun; 1790(6):478-84.
View in: PubMed

Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev. 2009 Feb; 19(1):1-3.
View in: PubMed

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
View in: PubMed

BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One. 2008; 3(12):e3949.
View in: PubMed

Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19372-7.
View in: PubMed

Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol Cancer Res. 2008 Oct; 6(10):1582-93.
View in: PubMed

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51.
View in: PubMed

A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55.
View in: PubMed

Unexpected pieces to the senescence puzzle. Cell. 2008 Jun 13; 133(6):958-61.
View in: PubMed

SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev. 2008 Jun; 27(2):137-46.
View in: PubMed

The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39.
View in: PubMed

Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008 May; 13(5):394-406.
View in: PubMed

The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008 Apr 16; 3(4):e2020.
View in: PubMed

Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64.
View in: PubMed

Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008 Apr; 14(4):152-60.
View in: PubMed

TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008 Jun 12; 27(26):3754-60.
View in: PubMed

Oncogenic transformation and experimental models of human cancer. Front Biosci. 2008 Jan 01; 13:71-84.
View in: PubMed

Liprin alpha1 interacts with PP2A B56gamma. . 2008 Feb 15; 7(4):525-32.
View in: PubMed

Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710.
View in: PubMed

Structural basis of PP2A inhibition by small t antigen. PLoS Biol. 2007 Aug; 5(8):e202.
View in: PubMed

The role of PP2A A subunits in tumor suppression. Cell Adh Migr. 2007 Jul-Sep; 1(3):140-1.
View in: PubMed

Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
View in: PubMed

The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 2007 Jun 01; 129(5):969-82.
View in: PubMed

Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics. 2007 Jun 15; 23(12):1451-8.
View in: PubMed

Cancer genomics: integrating form and function. Carcinogenesis. 2007 Jul; 28(7):1387-92.
View in: PubMed

Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol. 2007; 39(9):1562-8.
View in: PubMed

Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell. 2006 Nov 17; 127(4):759-73.
View in: PubMed

Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods. 2006 Oct; 3(10):777-9.
View in: PubMed

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006 Oct; 10(4):321-30.
View in: PubMed

Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 2006 Sep; 3(9):715-9.
View in: PubMed

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22.
View in: PubMed

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006 Jun 30; 125(7):1269-81.
View in: PubMed

Androgen-dependent regulation of Her-2/neu in prostate cancer cells. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10099.
View in: PubMed

Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 01; 66(11):5723-8.
View in: PubMed

PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem. 2006 Aug 11; 281(32):23003-12.
View in: PubMed

A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006 Mar 24; 124(6):1283-98.
View in: PubMed

Roots and stems: stem cells in cancer. Nat Med. 2006 Mar; 12(3):296-300.
View in: PubMed

Computational causal reasoning models of mechanisms of androgen stimulation in prostate cancer. Conf Proc IEEE Eng Med Biol Soc. 2006; 2006:38.
View in: PubMed

Involvement of PP2A in viral and cellular transformation. Oncogene. 2005 Nov 21; 24(52):7746-55.
View in: PubMed

Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15599-604.
View in: PubMed

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
View in: PubMed

Cancer genetics: Finding the right mix. Eur J Hum Genet. 2005 Oct; 13(10):1099-100.
View in: PubMed

Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005 Sep 15; 65(18):8183-92.
View in: PubMed

The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 2005 Sep; 9(3):327-38.
View in: PubMed

Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol. 2005 Aug; 25(15):6464-74.
View in: PubMed

Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther. 2005 Jul; 16(7):859-68.
View in: PubMed

Identification of the androgen-induced transcriptional program of human prostate cancer revealed by causal analysis. J Clin Oncol. 2005 Jun; 23(16_suppl):4637.
View in: PubMed

The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8222-7.
View in: PubMed

Analysis of telomeric single-strand overhang length in human endometrial cancers. FEBS Lett. 2005 May 23; 579(13):2959-64.
View in: PubMed

Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol. 2005 May; 54(2):85-93.
View in: PubMed

Genetic alterations in prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):220-9.
View in: PubMed

Telomere and telomerase dynamics in human cells. Curr Mol Med. 2005 Mar; 5(2):227-31.
View in: PubMed

Understanding transformation: progress and gaps. Curr Opin Genet Dev. 2005 Feb; 15(1):13-7.
View in: PubMed

Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
View in: PubMed

Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown. Cancer Res. 2004 Oct 01; 64(19):6978-88.
View in: PubMed

Nucleolin interacts with telomerase. J Biol Chem. 2004 Dec 03; 279(49):51508-15.
View in: PubMed

Cancer: surviving on the edge. Cancer Cell. 2004 Sep; 6(3):215-22.
View in: PubMed

Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol. 2004 Aug; 24(16):7024-31.
View in: PubMed

Indications for BRCA1 and BRCA2 mutation testing in hereditary breast and ovarian cancer families. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9720.
View in: PubMed

Functional genetics and experimental models of human cancer. Trends Mol Med. 2004 Jul; 10(7):344-50.
View in: PubMed

Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol. 2004 Jun; 24(12):5459-74.
View in: PubMed

Immortalized cells as experimental models to study cancer. Cytotechnology. 2004 Jun; 45(1-2):47-59.
View in: PubMed

Experimental models of human cancer. . 2004 May; 3(5):604-5.
View in: PubMed

Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis. Gene Ther. 2004 May; 11(9):739-45.
View in: PubMed

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004 Apr; 6(4):308-18.
View in: PubMed

A genetically defined model for human ovarian cancer. Cancer Res. 2004 Mar 01; 64(5):1655-63.
View in: PubMed

Targeting cancer with telomerase: commentary re Q. Huang et al., a novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res., 10: 1439-1445, 2004. Clin Cancer Res. 2004 Feb 15; 10(4):1203-5.
View in: PubMed

In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep. 2004 Feb; 11(2):297-302.
View in: PubMed

Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 2004 Feb; 5(2):127-36.
View in: PubMed

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 01; 10(3):828-39.
View in: PubMed

The origin of cancer. Cancer Treat Res. 2004; 122:1-22.
View in: PubMed

New Functions for Telomerase. Cancer Res Treat. 2003 Dec; 35(6):467-71.
View in: PubMed

Telomerase expression--only half the story. . 2003 Nov-Dec; 2(6):685-6.
View in: PubMed

Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther. 2003 Sep; 10(18):1543-50.
View in: PubMed

Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther. 2003 Aug; 10(15):1216-24.
View in: PubMed

Telomerase maintains telomere structure in normal human cells. Cell. 2003 Jul 25; 114(2):241-53.
View in: PubMed

Evolving views of telomerase and cancer. Trends Cell Biol. 2003 Jun; 13(6):289-94.
View in: PubMed

Telomerase and tumorigenesis. Cancer Lett. 2003 May 15; 194(2):163-72.
View in: PubMed

Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003 May 15; 21(10):2034-43.
View in: PubMed

Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003 May; 3(5):483-95.
View in: PubMed

SV40 early region oncoproteins and human cell transformation. Histol Histopathol. 2003 04; 18(2):541-50.
View in: PubMed

Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003 Apr; 9(4):493-501.
View in: PubMed

Chemosensitivity linked to p73 function. Cancer Cell. 2003 Apr; 3(4):403-10.
View in: PubMed

Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol. 2003 Apr; 23(8):2859-70.
View in: PubMed

Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet. 2003 Apr; 33(4):492-6.
View in: PubMed

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003 Mar; 3(3):285-96.
View in: PubMed

Rules for making human tumor cells. N Engl J Med. 2002 Nov 14; 347(20):1593-603.
View in: PubMed

Empty pockets yield more telomere change. . 2002 Nov-Dec; 1(6):406-7.
View in: PubMed

Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002 Oct 01; 99(20):12606-11.
View in: PubMed

Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002 Sep; 8(9):979-86.
View in: PubMed

Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 2002 Jul 04; 21(29):4577-86.
View in: PubMed

A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol. 2002 Jul; 22(14):5157-72.
View in: PubMed

Senescence, telomere shortening and telomere maintenance. . 2002 Jul-Aug; 1(4):398-400.
View in: PubMed

Immortalization and transformation of human cells. Mol Cells. 2002 Jun 30; 13(3):351-61.
View in: PubMed

Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002 May; 2(5):331-41.
View in: PubMed

Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002 Apr; 22(7):2111-23.
View in: PubMed

Prospects for anti-neoplastic therapies based on telomere biology. Curr Cancer Drug Targets. 2002 Mar; 2(1):1-17.
View in: PubMed

Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res. 2001 Dec 15; 61(24):8838-44.
View in: PubMed

Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001 Dec 01; 61(23):8366-70.
View in: PubMed

Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001 Nov; 7(11):3343-8.
View in: PubMed

Telomerase and cancer: where and when? Clin Cancer Res. 2001 Oct; 7(10):2953-4.
View in: PubMed

Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest. 2001 Sep; 108(5):725-32.
View in: PubMed

Telomerase activation, cellular immortalization and cancer. Ann Med. 2001 Mar; 33(2):123-9.
View in: PubMed

The Saccharomyces cerevisiae WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase. EMBO J. 2001 Feb 15; 20(4):905-13.
View in: PubMed

Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001 Jan 01; 15(1):50-65.
View in: PubMed

Genes involved in senescence and immortalization. Curr Opin Cell Biol. 2000 Dec; 12(6):705-9.
View in: PubMed

Complications during root canal irrigation--literature review and case reports. Int Endod J. 2000 May; 33(3):186-93.
View in: PubMed

Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol. 2000 Feb; 20(4):1436-47.
View in: PubMed

Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct; 5(10):1164-70.
View in: PubMed

Creation of human tumour cells with defined genetic elements. Nature. 1999 Jul 29; 400(6743):464-8.
View in: PubMed

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun; 10(6):673-9.
View in: PubMed

Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14723-8.
View in: PubMed

Diagnosis in Oncology. Leukemia cutis. J Clin Oncol. 1997 May; 15(5):2170-1.
View in: PubMed

Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation. Biophys J. 1995 Feb; 68(2):459-70.
View in: PubMed

Separable portions of the CD2 cytoplasmic domain involved in signaling and ligand avidity regulation. J Exp Med. 1993 Nov 01; 178(5):1831-6.
View in: PubMed

T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2. Semin Immunol. 1993 Aug; 5(4):249-61.
View in: PubMed

The complete sequences of plasmids pFNeo and pMH-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines. Gene. 1993 May 30; 127(2):267-8.
View in: PubMed

Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58. J Immunol. 1993 Apr 01; 150(7):2607-19.
View in: PubMed

CD4, CD8 and CD2 in T cell adhesion and signaling. Curr Top Microbiol Immunol. 1993; 184:223-33.
View in: PubMed

A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):7179-83.
View in: PubMed

Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science. 1992 Jun 26; 256(5065):1805-7.
View in: PubMed

CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature. 1991 Nov 21; 354(6350):233-5.
View in: PubMed

Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3',5'-cyclic monophosphate production in T lymphocytes. J Immunol. 1991 Jul 01; 147(1):14-21.
View in: PubMed

Cloned cDNA sequence for the human mesothelial protein 'mesosecrin' discloses its identity as a plasminogen activator inhibitor (PAI-1) and a recent evolutionary change in transcript processing. J Cell Sci. 1989 Sep; 94 ( Pt 1):1-10.
View in: PubMed

Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol. 1987 Feb; 104(2):263-75.
View in: PubMed

Cloning and sequence of DNA encoding structural proteins of the autonomous parvovirus feline panleukopenia virus. J Virol. 1985 Sep; 55(3):574-82.
View in: PubMed

Clinical signs for the early recognition of cancer of the oral cavity. Int Dent J. 1977 Jun 02; 27(2):165-71.
View in: PubMed

[Blood sugar and plasma insulin levels in children following the oral administration of glybenclamide (HB 419)]. Z Kinderheilkd. 1970; 108(1):32-40.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1538
Boston, MA 02215
Get Directions

Ratings

Top